IP Library Granted Patent US 10,335,498
Granted Patent B2
US 10,335,498 · App. 14/983,021 · Granted Jul 2, 2019

RNA based biomaterial for tissue engineering applications

Inventors: Satheesh Elangovan (Iowa City, IA); Sheetal Reginald R D'mello (Silver Spring, MD); Anh-Vu T Do (Iowa City, IA); Liu Hong (Coralville, IA); Behnoush Khorsand-Sourkohi (Iowa City, IA); Aliasger K Salem (Coralville, IA); Michael Kormann (Tübingen, DE)
Assignee: University of Iowa Research Foundation
A61K48/0041A61K31/712A61K31/7115A61K48/00A61K48/005A61L27/54A61L27/58A61K38/00A61L2300/258A61L2300/414A61L2300/62A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,335,498
App. No.
14/983,021
Granted
Jul 2, 2019
Kind
B2
Abstract

The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.

Claims (18)

1. A composition comprising chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle comprising polyamidoamine (PAMAM) dendrimers or polyethylenimine (PEI) and a biocompatible, bioresorbable scaffold comprising collagen, wherein at least 90% of the cytosine (C) and uridine (U) in the cmRNA are substituted with 5-methylcytidine-5 triphosphate, pseudouridine-5-triphosfate, or a combination thereof, and wherein the composition comprises sequences that encode at least two proteins selected from the group consisting of a BMP, osteocalcin, type I collagen, core binding factor, PDGF, TGF-beta, antibody to sclerostin or the antigen binding fragment thereof, antibody to receptor activator of nuclear factor kappa-B ligand (RANKL) or the antigen binding fragment thereof, osterix, HGF, bFGF, NGF, neuregulin, or activin.

2. The composition of claim 1 wherein the delivery vehicle comprises microparticles or nanoparticles.

3. The composition of claim 1 wherein the delivery vehicle further comprises cationic or non-cationic polymers.

4. The composition of claim 1 wherein the delivery vehicle further comprises PEI, chitosan, cyclodextrin or dendrimers.

5. The composition of claim 1 wherein the delivery vehicle further comprises PLGA, PEI, PLA, or PAMAM.

6. The composition of claim 1 wherein the PEI comprises branched PEI.

7. The composition of claim 1 wherein the delivery vehicle comprises complexes of cmRNA and the PEI.

8. The composition of claim 1 wherein the cmRNA encodes at least one of a BMP or PDGF.

9. The composition of claim 1 wherein the scaffold further comprises proteoglycan, alginate, chitosan or extracellular matrix.

10. The composition of claim 1 wherein the scaffold further comprises a synthetic polymer.

11. The composition of claim 10 wherein the synthetic polymer comprises PLA, PGLA, PLLA or polystyrene.

12. The method of claim 2 wherein the microparticles or nanoparticles comprise PLGA.

13. The method of claim 12 wherein the collagen scaffold comprises the microparticles or nanoparticles which comprise the cmRNA encapsulated in or complexed with PAMAM dendrimers or PEI.

14. A method to enhance tissue regeneration in vivo comprising administering an effective amount of the composition of claim 1 to a tissue of a mammal in need thereof.

15. The method of claim 14 wherein the tissue is bone.

16. The method of claim 14 wherein the composition is administered to a bone defect in the mammal or introduced to the jaw of the mammal.

17. A method to enhance tissue regeneration ex vivo comprising introducing an effective amount of the composition of claim 1 to cells of a mammal.

18. A device coated with the composition of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2017
From: EBERHARD- KARLS- UNIVERSITÄT TÜBINGENMEDIZINISCHE FAKULTÄT
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 043190/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2017
From: ELANGOVAN, SATHEESH; D'MELLO, SHEETAL REGINALD R; DO, ANH-VU T; HONG, LIU; KHORSAND-SOURKOHI, BEHNOUSH; SALEM, ALIASGER K
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 042810/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2017
From: KORMANN, MICHAEL
To: EBERHARD- KARLS- UNIVERSITÄT TÜBINGENMEDIZINISCHE FAKULTÄT
Reel/Frame 042810/0386 →
Continuity (2)
Provisional Application 62097405 · Dec 29, 2014
Related Publication 20160220698A1 · Aug 4, 2016
Cited By (1)
US 12,624,015